Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells $306,423.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Michael Taylor sold 13,095 shares of CeriBell stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $23.40, for a total value of $306,423.00. Following the completion of the transaction, the director directly owned 48,478 shares of the company’s stock, valued at approximately $1,134,385.20. This represents a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Joseph Michael Taylor also recently made the following trade(s):

• On Thursday, June 11th, Joseph Michael Taylor sold 5,500 shares of CeriBell stock. The stock was sold at an average price of $18.41, for a total transaction of $101,255.00.

CeriBell Price Performance

Shares of CBLL opened at $23.33 on Monday. The company’s 50-day simple moving average is $18.93 and its 200-day simple moving average is $19.09. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $24.33. The stock has a market capitalization of $895.41 million, a PE ratio of -13.26 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Analysts forecast that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on CBLL shares. Canaccord Genuity Group increased their price objective on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. BTIG Research reissued a “buy” rating and set a $28.00 target price on shares of CeriBell in a research note on Tuesday, August 11th. Finally, Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CBLL. BlackRock Inc. acquired a new position in shares of CeriBell during the 2nd quarter worth about $37,657,000. Bank of New York Mellon Corp raised its position in shares of CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after acquiring an additional 1,162,200 shares in the last quarter. KCM Capital Inc purchased a new stake in CeriBell during the fourth quarter worth approximately $21,930,000. TimesSquare Capital Management LLC acquired a new position in CeriBell in the second quarter valued at approximately $15,182,000. Finally, Royce & Associates LP acquired a new position in CeriBell in the fourth quarter valued at approximately $11,695,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.